AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05715242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Easier Red Zone Food Goal
Description: Participants will receive an easier daily Red Zone Food goal.
Study NCT05715242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harder Red Zone Food Goal
Description: Participants will receive a more challenging daily Red Zone Food goal.
Study NCT05882305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous monocyte-derived DCs pulsed withEBV-associated antigen
Description: Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
Study NCT05827042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis
Description: Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
Study NCT05827042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy
Study NCT05827042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy
Study NCT04678232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Processes and Transition to Health (PATH)
Description: See arm/group description for details regarding this intervention
Study NCT05727761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone-metformin
Description: Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
Study NCT05420298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: All participants will receive only single session of cervical mobilization
Study NCT05420298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cervical manipulation
Description: All participants will receive only single session of cervical manipulation
Study NCT04173975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With knee exoskeleton
Description: BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
Study NCT04751929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenously Day 1 of 21 day cycle
Study NCT05386680 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
Study NCT05916950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thor laser atherectomy
Description: Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
Study NCT06266364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active VNS stimulation
Description: The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
Study NCT06266364 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VNS stimulation
Description: The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
Study NCT05133050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: We use ACEI: ramipril, in this prospective, randomized, controlled and multicenter clinical trial to access the safety and efficacy in Alport syndrome patients carried COL4A3/COL4A4/COL4A5 variants.
Study NCT05275439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study NCT06352359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-841
Description: ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
Study NCT05688280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for Injection
Description: 4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
Study NCT05088915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD (PCIP)
Description: This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb.
Study NCT05088915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study NCT06029127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered intravenously at protocol defined dose
Study NCT06029127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously
Study NCT06029127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 milligrams per square meter (mg/m\^2) administered intravenously
Study NCT06029127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramucirumab
Description: 10 mg/kg administered intravenously
Study NCT06029127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally at protocol defined dose
Study NCT04109027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainStrong-GSR
Description: Goal-directed State Regulation Training (GSR)
Study NCT04109027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BrainStrong-OPT
Description: Optimization of Brain Functioning (OPT)
Study NCT04454684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.
Study NCT04454684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-directive therapy
Description: Non-directive therapy will be conducted during Experimental Sessions.
Study NCT04454684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
Study NCT04506151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-Opt
Description: 12-week behavioral intervention
Study NCT04506151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Healthy Living
Study NCT06140524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion
Study NCT04849221 — intervention group
Intervention type: OTHER
Intervention: Tympanometry measurement in both ears
Description: Measurement once or twice a day and at every change of more than 10 mmHg in ICP, over the entire period of time that ICP is measured by a probe or DVE
Study NCT04849221 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical and paraclinical data
Description: Patient: gender, weight/height, age, etiology of ICP entry, reason for ICP monitoring, presence of external (otoscopy), middle (otoscopy + CT) or internal (CT) ear abnormality, presence of inclusion and non-inclusion criteria, measurement of patient tilt.~healthy subjects: gender, weight/height, age, presence of abnormality of the external (otoscopy), middle (otoscopy) or internal ear (questioning), presence of inclusion and non-inclusion criteria...
Study NCT04849221 — intervention group
Intervention type: OTHER
Intervention: Intracranial pressure reading (ICP)
Description: a single measure
Study NCT05556915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided AVF cannulation method
Description: For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
Study NCT05556915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional AVF cannulation method
Description: The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
Study NCT06391684 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social/non social; predictable vs unpredictable
Description: Task 1: social predictable vs social unpredictable ; Task2 a. social \& b. non social, predictable/unpredictable (for both)
Study NCT05509725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Description: Participants will be asked to take 2 doses daily
Study NCT05509725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take 2 doses daily
Study NCT05762848 — intervention group
Intervention type: DEVICE
Intervention: Mobile Phone Head Circumference App
Description: Measurement of Head circumference of Babies/Infants with a mobile phone application.
Study NCT06340074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HELM
Description: HELM is a 9-month, data-driven organizational and leadership implementation strategy that entails eight core components: 1) Assessment and Feedback. 2) Initial Training. 3) Leadership Development Plan. 4) Individual Coaching. 5) Group Coaching. 6) Organizational Strategy Development. 7) Professional Learning Collaboratives. 8) Graduation.
Study NCT06340074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Implementation Attention Control (IAC)
Description: Schools assigned to the IAC condition received an online, self-paced, independent studies program broadly focused on leadership and management. The program did not specifically discuss implementation leadership or climate. The program included four content modules hosted on a web-based learning portal: 1) Motivating and Engaging Employees, 2) Authentic Leadership, 3) Managing Diverse Teams, and 4) Fostering an Idea Culture. Each module consisted of one content-specific 60-minute webinar.
Study NCT05673408 — intervention group
Intervention type: DEVICE
Intervention: Philips IntelliVue X3 Patient Monitor
Description: All subjects enrolled in this study will receive one Philips non-invasive blood pressure cuff. This cuff will be connected via compatible hose to the Philips IntelliVue X3 monitor hosting the released or investigational NIBP algorithm. The invasive blood pressure from the radial arterial line will also be connected to the Philips IntelliVue X3 monitor. The Philips IntelliVue X3 monitor will in turn be connected to a laptop for data collection.
Study NCT05664932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
Description: Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
Study NCT05664932 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZF2001
Description: Intramuscular injection of ZF2001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
Study NCT04332211 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
Study NCT04332211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
Study NCT04332211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 MG
Description: administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
Study NCT04332211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
Study NCT05034848 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Assessment of BMD by DXA and HRpQCT
Description: * DXA : BMD assessment at the left hip, rachis and both legs~* HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs~* Biological samples
Study NCT06614049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications
Description: Receive personalised feedback and educational content curated by local clinicians and pharmacists through the CADENCE D-PHA app coupled with six sessions of human coaching on top of usual clinical care for lipid management over 6 months
Study NCT04704700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repair of a cuff tear
Description: Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
Study NCT04704700 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repair of a cuff tear
Description: Group (Control): standard Arthroscopic repair of the cuff rotator
Study NCT06624579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: confocal endomicroscopy
Description: The study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in UC patients. Confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing.
Study NCT06719037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-Surgi Plus endoscopic surgery
Description: Endo-Surgi Plus endoscopic surgery, as a new type of percutaneous endoscopic lumbar discectomy (PELD), features a larger working channel and represents an optimized single-channel endoscopic technique. However, it still has the limitations inherent in single-channel endoscopy.
Study NCT06719037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral biportal endoscopic surgery
Description: Unilateral biportal endoscopic discectomy (UBE) is characterized by its separate endoscopic and working channels, and the ability to use traditional open instruments, making it a convenient and versatile technique. It is a commonly used spinal endoscopic surgery in clinical practice.
Study NCT06719037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microdiscectomy
Description: Microdiscectomy (MD) is a mature minimally invasive technique that uses a microscope to treat lumbar spinal stenosis. As early as 1999, prospective randomized controlled studies confirmed that it has equally excellent clinical efficacy compared to open surgery, with less surgical trauma. It is currently the classic minimally invasive surgical approach for treating lumbar spinal stenosis.
Study NCT06766578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy(5×3Gy radiotherapy)
Description: Radiotherapy: 5×3Gy. The preoperative radiotherapy target was outlined by radiotherapy physicians according to the NCCN Guidelines for Gastric/esophagogastric Junction Tumor 2024 edition and the surgeon's opinions. The first and third cycles were 5×3Gy.
Study NCT06766578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)
Description: The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
Study NCT06766578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
Study NCT06766578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy(SOX chemotherapy)
Description: Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
Study NCT06765772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
Study NCT06765772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block
Description: the patient will recieve ultrasound guided rectus sheath block. An 18-gauge needle will be introduced- in plane- just below the costal margin at an angle of approximately 45 degrees to the skin between the rectus abdominis muscle and posterior rectus sheath. 10 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
Study NCT06763861 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Description: Biopsies from EAS
Study NCT06766526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy
Description: An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.
Study NCT06766526 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive support
Description: Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.
Study NCT06765174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Drain placement (Example: Q-vac)
Description: After thyroid surgery we pust drain at bed of surgery to monitor post operative bleeding.
Study NCT06766630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk fibroin surgical mesh
Description: This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
Study NCT06764251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + SOX
Description: tislelizumab combined with SOX
Study NCT06768853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node dissection based on the guidelines
Description: During surgery, mediastinal lymph nodes will be dissected based on the NCCN guidelines (2023) .
Study NCT06768853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node dissection based on the model
Description: During surgery, lymph nodes will be dissected based on the predicted lymph node status by the model.
Study NCT04104022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.